Transvaginal Ultrasound Cervical Length Measurements in Twin Gestations

NCT ID: NCT02372422

Last Updated: 2015-02-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

125 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-10-31

Study Completion Date

2007-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine if the use of routine transvaginal cervical length ultrasound can be used to prevent preterm deliveries in twin gestations.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized controlled trial to determine whether there is a difference in the rate of preterm birth among women with twin pregnancies whose clinicians are aware of transvaginal ultrasound cervical length measurements compared to those managed without this information. The study group had transvaginal cervical length ultrasound monthly from 16-28 weeks and were managed with a standard algorithm for activity restriction and cerclage depending on the cervical length. The control group had digital cervical exams and routine transvaginal cervical length ultrasound was not utilized. The primary outcome was the mean length of gestation. Secondary outcomes included percentage of deliveries \< 35 weeks, maternal and neonatal outcomes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pregnancy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Transvaginal Cervical Length Group

Clinicians managing the patients were aware of the transvaginal cervical length ultrasound measurements.

Group Type EXPERIMENTAL

Transvaginal ultrasound determination of cervical length

Intervention Type OTHER

Transvaginal ultrasound was used to measure the length of the cervix from the internal to external os relying on a standard approach and clinicians caring for the patients were made aware of the results.

Routine Care

Clinicians managing the patients were not aware of any transvaginal cervical length ultrasound measurements.

Group Type OTHER

Routine care

Intervention Type OTHER

Routine prenatal care of twins. Digital exams were permitted, but transvaginal ultrasound assessment of cervical length was not.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Transvaginal ultrasound determination of cervical length

Transvaginal ultrasound was used to measure the length of the cervix from the internal to external os relying on a standard approach and clinicians caring for the patients were made aware of the results.

Intervention Type OTHER

Routine care

Routine prenatal care of twins. Digital exams were permitted, but transvaginal ultrasound assessment of cervical length was not.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Twin pregnancy
* Gestational age \< 20 weeks

Exclusion Criteria

* History of incompetent cervix with plans to place a cerclage
* History of possible cervical incompetence with preexisting plans to monitor cervical length
* Prior preterm birth at \< 28 weeks gestational age
* Plans to leave the area before delivery
* Known major fetal anomaly
* Known diagnosis of twin-twin transfusion syndrome
* Age \< 18
* Monoamniotic twins
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Madigan Army Medical Center

FED

Sponsor Role collaborator

Wright-Patterson Medical Center

UNKNOWN

Sponsor Role collaborator

William H. Barth, Jr., M.D., Col(ret), USAF, MC

FED

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

William H. Barth, Jr., M.D., Col(ret), USAF, MC

William H. Barth, Jr., M.D., Col(ret), USAF, MC

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Michael C Gordon, M.D.

Role: PRINCIPAL_INVESTIGATOR

59th Medical Wing

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FWH20020099H

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.